A particularity of this cohort was the absence of HER2 scores 3+ by immunohistochemistry, related to the fact the protocol was optimized to avoid HER2 positive signals in the normal mammary gland, as recommended for breast cancers. Here, ERBB2 is linked to breast cancer.